218 related articles for article (PubMed ID: 28283597)
1. Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.
Lloyd TE; Pinal-Fernandez I; Michelle EH; Christopher-Stine L; Pak K; Sacktor N; Mammen AL
Neurology; 2017 Apr; 88(15):1454-1460. PubMed ID: 28283597
[TBL] [Abstract][Full Text] [Related]
2. Inclusion body myositis: clinical and pathological boundaries.
Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ
Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies.
Lee SA; Lee HJ; Suh BC; Shin HY; Kim SW; Yoon BA; Choi YC; Park HJ
PLoS One; 2023; 18(4):e0284409. PubMed ID: 37058449
[TBL] [Abstract][Full Text] [Related]
4. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
[TBL] [Abstract][Full Text] [Related]
6. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
Amlani A; Choi MY; Tarnopolsky M; Brady L; Clarke AE; Garcia-De La Torre I; Mahler M; Schmeling H; Barber CE; Jung M; Fritzler MJ
Front Immunol; 2019; 10():745. PubMed ID: 31024569
[No Abstract] [Full Text] [Related]
7. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome.
Johnson RW; Williams FM; Kazi S; Dimachkie MM; Reveille JD
Arthritis Rheum; 2003 Apr; 49(2):172-8. PubMed ID: 12687507
[TBL] [Abstract][Full Text] [Related]
8. Cervicobrachial polymyositis.
Khadilkar SV; Gupta N; Yadav RS
J Clin Neuromuscul Dis; 2014 Dec; 16(2):59-68. PubMed ID: 25415516
[TBL] [Abstract][Full Text] [Related]
9. Inclusion body myositis.
Dimachkie MM; Barohn RJ
Curr Neurol Neurosci Rep; 2013 Jan; 13(1):321. PubMed ID: 23250766
[TBL] [Abstract][Full Text] [Related]
10. Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.
Michelle EH; Pinal-Fernandez I; Casal-Dominguez M; Albayda J; Paik JJ; Tiniakou E; Adler B; Mecoli CA; Danoff SK; Christopher-Stine L; Mammen AL; Lloyd TE
Neurology; 2023 Mar; 100(13):e1406-e1417. PubMed ID: 36690456
[TBL] [Abstract][Full Text] [Related]
11. Inclusion body myositis: clinical and histopathological features of 36 patients.
Beyenburg S; Zierz S; Jerusalem F
Clin Investig; 1993 May; 71(5):351-61. PubMed ID: 8389626
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype.
Troyanov Y; Landon-Cardinal O; Fritzler MJ; Ferreira J; Targoff IN; Rich E; Goulet M; Goulet JR; Bourré-Tessier J; Robitaille Y; Drouin J; Albert A; Senécal JL
Medicine (Baltimore); 2017 Jan; 96(3):e5694. PubMed ID: 28099331
[TBL] [Abstract][Full Text] [Related]
13. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis.
Mescam-Mancini L; Allenbach Y; Hervier B; Devilliers H; Mariampillay K; Dubourg O; Maisonobe T; Gherardi R; Mezin P; Preusse C; Stenzel W; Benveniste O
Brain; 2015 Sep; 138(Pt 9):2485-92. PubMed ID: 26198592
[TBL] [Abstract][Full Text] [Related]
14. T-Cell-Mediated Inflammatory Myopathies in HIV-Positive Individuals: A Histologic Study of 19 Cases.
Hiniker A; Daniels BH; Margeta M
J Neuropathol Exp Neurol; 2016 Mar; 75(3):239-45. PubMed ID: 26843609
[TBL] [Abstract][Full Text] [Related]
15. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.
van der Meulen MF; Hoogendijk JE; Moons KG; Veldman H; Badrising UA; Wokke JH
Neuromuscul Disord; 2001 Jul; 11(5):447-51. PubMed ID: 11404115
[TBL] [Abstract][Full Text] [Related]
16. ['Inclusion body'-myositis].
Badrising UA; Maat-Schieman ML; van Duinen SG; van Dijk JG; Verschuuren JJ; Wintzen AR
Ned Tijdschr Geneeskd; 1998 Mar; 142(11):553-7. PubMed ID: 9623110
[TBL] [Abstract][Full Text] [Related]
17. [Sporadic inclusion body myositis and amyloid].
Aoki M; Suzuki N
Brain Nerve; 2014 Jul; 66(7):739-48. PubMed ID: 24998819
[TBL] [Abstract][Full Text] [Related]
18. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.
Larman HB; Salajegheh M; Nazareno R; Lam T; Sauld J; Steen H; Kong SW; Pinkus JL; Amato AA; Elledge SJ; Greenberg SA
Ann Neurol; 2013 Mar; 73(3):408-18. PubMed ID: 23596012
[TBL] [Abstract][Full Text] [Related]
19. [Polymyositis, dermatomyositis and inclusion body myositis, nosological aspects].
Eymard B
Presse Med; 2003 Oct; 32(35):1656-67. PubMed ID: 14631270
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory myopathies: evaluation and management.
Greenberg SA
Semin Neurol; 2008 Apr; 28(2):241-9. PubMed ID: 18351525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
